These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21352322)

  • 21. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 22. Severe agranulocytosis as a rare side effect of pegylated interferon therapy for chronic hepatitis B.
    Zizer E; Bommer M; Barth T; Dikopoulos N
    Z Gastroenterol; 2011 May; 49(5):596-8. PubMed ID: 21557170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Puoti M; Babudieri S; Rezza G; Viale P; Antonini MG; Maida I; Rossi S; Zanini B; Putzolu V; Fenu L; Baiguera C; Sassu S; Carosi G; Mura MS
    Antivir Ther; 2004 Aug; 9(4):627-30. PubMed ID: 15456094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Embolia cutis medicamentosa after subcutaneous injection of pegylated interferon-alpha].
    Sonntag M; Hodzic-Avdagic N; Bruch-Gerharz D; Neumann NJ
    Hautarzt; 2005 Oct; 56(10):968-9. PubMed ID: 16142495
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon associated lichen planus at the injection site.
    Ergül B; Koçak E; Akbal E; Köklü S; Astarci HM
    Acta Gastroenterol Belg; 2011 Dec; 74(4):591-2. PubMed ID: 22319976
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
    Lübbe J; Kerl K; Negro F; Saurat JH
    Br J Dermatol; 2005 Nov; 153(5):1088-90. PubMed ID: 16225644
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pegylated interferon alfa-induced psoriasis].
    González-López MA; González-Vela MC; López-Escobar M; Fernando Val-Bernal J
    Med Clin (Barc); 2007 Sep; 129(9):358. PubMed ID: 17910858
    [No Abstract]   [Full Text] [Related]  

  • 32. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 33. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
    Ji F; Li Z; Xue H; Liu L; Deng H
    South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pegylated interferon-alpha for the treatment of chronic hepatitis C].
    Weis NM; Krarup HB; Skinhøj P
    Ugeskr Laeger; 2003 Oct; 165(44):4211-5. PubMed ID: 14621552
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
    Shafa S; Borum ML; Igiehon E
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):122-3. PubMed ID: 19959941
    [No Abstract]   [Full Text] [Related]  

  • 37. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 38. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.